title: [Effect of nordy on FPR function of malignant human glioma cell line U87].
abstract: Nordy is a synthesized chrial compound. To investigate the effects of nordy (25 - 100 micromol x L(-1)) on the function of formylpeptide receptor (FPR) of malignant human glioma cells, human glioblastoma cell line U87 was used to detect its proliferation, migration, calcium mobilization, vascular endothelial growth factor (VEGF) mRNA and protein levels after activation of FPR by its agonist N-formyl-methionyl-leucyl-phenylalanine (fMLF). Cell proliferation, migration ability, VEGF mRNA, VEGF protein and calcium mobilization were evaluated by cell counting, chemotaxis assay, RT-PCR, ELISA and spectrometry. Nordy (50 - 100 micromol x L(-1)) potently inhibited the proliferation, migration and calcium mobilization of U87 cells induced by fMLF (P < 0.05). Moreover, 100 micromol x L(-1) nordy showed a significantly impaired VEGF mRNA expression and protein secretion induced by fMLF (P < 0.05). Nordy could inhibit FPR functioning in glioma cell proliferation, migration and angiogenesis, which might be a possible mechanism of its anti-cancer effects.
authors.affiliation: Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. chenjh-110@263.net
authors.forename: Jian-Hong
authors.initials: JH
authors.lastname: Chen
authors.forename: Xiu-Wu
authors.initials: XW
authors.lastname: Bian
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Yao
authors.forename: Shi-Xin
authors.initials: SX
authors.lastname: Yang
authors.forename: Chang-Rong
authors.initials: CR
authors.lastname: Xu
authors.forename: Xiang-Dong
authors.initials: XD
authors.lastname: Zhou
authors.forename: Yi-Fang
authors.initials: YF
authors.lastname: Ping
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009637:Masoprocol / Q000031:analogs & derivatives* / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D044042:Receptors, Formyl Peptide / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013053:Spectrophotometry / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D012333:RNA, Messenger; D044042:Receptors, Formyl Peptide; D042461:Vascular Endothelial Growth Factor A; C510003:nordy; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009637:Masoprocol; D002118:Calcium